Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer ; volume:10 ; number:1 ; day:13 ; month:7 ; year:2024 ; pages:1-7 ; date:12.2024
npj Breast cancer ; 10, Heft 1 (13.7.2024), 1-7, 12.2024
- Creator
-
Fasching, Peter Andreas
Hu, Chunling
Hart, Steven N.
Ruebner, Matthias
Polley, Eric C.
Gnanaolivu, Rohan D.
Hartkopf, Andreas
Huebner, Hanna
Janni, Wolfgang
Hadji, Peyman
Tesch, Hans
Uhrig, Sabrina
Ettl, Johannes
Lux, Michael P.
Lüftner, Diana
Wallwiener, Markus
Wurmthaler, Lena A.
Goossens, Chloë
Müller, Volkmar
Beckmann, Matthias W.
Hein, Alexander
Anetsberger, Daniel
Belleville, Erik
Wimberger, Pauline
Untch, Michael
Ekici, Arif Bülent
Kolberg, Hans-Christian
Hartmann, Arndt
Ţăran, Florin-Andrei
Fehm, Tanja
Wallwiener, Diethelm
Brucker, Sara Y.
Schneeweiss, Andreas
Häberle, Lothar
Couch, Fergus J.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41523-024-00667-x
- URN
-
urn:nbn:de:101:1-2410020930174.169547062867
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:32 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Fasching, Peter Andreas
- Hu, Chunling
- Hart, Steven N.
- Ruebner, Matthias
- Polley, Eric C.
- Gnanaolivu, Rohan D.
- Hartkopf, Andreas
- Huebner, Hanna
- Janni, Wolfgang
- Hadji, Peyman
- Tesch, Hans
- Uhrig, Sabrina
- Ettl, Johannes
- Lux, Michael P.
- Lüftner, Diana
- Wallwiener, Markus
- Wurmthaler, Lena A.
- Goossens, Chloë
- Müller, Volkmar
- Beckmann, Matthias W.
- Hein, Alexander
- Anetsberger, Daniel
- Belleville, Erik
- Wimberger, Pauline
- Untch, Michael
- Ekici, Arif Bülent
- Kolberg, Hans-Christian
- Hartmann, Arndt
- Ţăran, Florin-Andrei
- Fehm, Tanja
- Wallwiener, Diethelm
- Brucker, Sara Y.
- Schneeweiss, Andreas
- Häberle, Lothar
- Couch, Fergus J.
- SpringerLink (Online service)
Other Objects (12)
The impact of single tumor cell dissemination on individualized systemic breast cancer treatment
Tucatinib (Tukysa) bei HER2-positivem Brustkrebs : hochwirksame Behandlungsoption für metastasierte Patienten, auch bei ZNS-Metastasierung
Trastuzumab-Deruxtecan (Enhertu) - Paradigmenwechsel: neue Optionen bei der Behandlung von Patient*innen mit nicht operablem, metastasiertem HER2-low Mammakarzinom
Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer
Trastuzumab deruxtecan (Enhertu®) : Paradigmenwechsel: neue Optionen bei der Behandlung von Patient*innen mit nicht operablem, metastasiertem HER2-low Mammakarzinom
Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer – Controversies and Standards in Healthcare
Systemic therapy of premenopausal patients with early stage hormone receptor-positive, HER2-negative breast cancer – controversies and standards in healthcare
Systemic therapy of premenopausal patients with early stage hormone receptor-positive, HER2-negative breast cancer: controversies and standards in healthcare
Characterization of germ cell differentiation in the male mouse through single-cell RNA sequencing
Circulating and Disseminated Tumor Cells in Breast Carcinoma : Report from the Consensus Conference on Tumor Cell Dissemination during the 39th Annual Meeting of the German Society of Senology, Berlin, 27 June 2019
Update breast cancer 2023 Part 1 – early stage breast cancer
BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing
The impact of single tumor cell dissemination on individualized systemic breast cancer treatment
Tucatinib (Tukysa) bei HER2-positivem Brustkrebs : hochwirksame Behandlungsoption für metastasierte Patienten, auch bei ZNS-Metastasierung
Trastuzumab-Deruxtecan (Enhertu) - Paradigmenwechsel: neue Optionen bei der Behandlung von Patient*innen mit nicht operablem, metastasiertem HER2-low Mammakarzinom
Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer
Trastuzumab deruxtecan (Enhertu®) : Paradigmenwechsel: neue Optionen bei der Behandlung von Patient*innen mit nicht operablem, metastasiertem HER2-low Mammakarzinom
Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer – Controversies and Standards in Healthcare
Systemic therapy of premenopausal patients with early stage hormone receptor-positive, HER2-negative breast cancer – controversies and standards in healthcare
Systemic therapy of premenopausal patients with early stage hormone receptor-positive, HER2-negative breast cancer: controversies and standards in healthcare
Characterization of germ cell differentiation in the male mouse through single-cell RNA sequencing
Circulating and Disseminated Tumor Cells in Breast Carcinoma : Report from the Consensus Conference on Tumor Cell Dissemination during the 39th Annual Meeting of the German Society of Senology, Berlin, 27 June 2019
Update breast cancer 2023 Part 1 – early stage breast cancer
BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing
The impact of single tumor cell dissemination on individualized systemic breast cancer treatment
Tucatinib (Tukysa) bei HER2-positivem Brustkrebs : hochwirksame Behandlungsoption für metastasierte Patienten, auch bei ZNS-Metastasierung
Trastuzumab-Deruxtecan (Enhertu) - Paradigmenwechsel: neue Optionen bei der Behandlung von Patient*innen mit nicht operablem, metastasiertem HER2-low Mammakarzinom
Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer
Trastuzumab deruxtecan (Enhertu®) : Paradigmenwechsel: neue Optionen bei der Behandlung von Patient*innen mit nicht operablem, metastasiertem HER2-low Mammakarzinom
Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer – Controversies and Standards in Healthcare
Systemic therapy of premenopausal patients with early stage hormone receptor-positive, HER2-negative breast cancer – controversies and standards in healthcare
Systemic therapy of premenopausal patients with early stage hormone receptor-positive, HER2-negative breast cancer: controversies and standards in healthcare
Characterization of germ cell differentiation in the male mouse through single-cell RNA sequencing
Circulating and Disseminated Tumor Cells in Breast Carcinoma : Report from the Consensus Conference on Tumor Cell Dissemination during the 39th Annual Meeting of the German Society of Senology, Berlin, 27 June 2019
Update breast cancer 2023 Part 1 – early stage breast cancer